Study: 18F-FLT helps track patients' response to treatment

10/8/2009 | HealthImaging.com

An Australian study that compared results of baseline PET/CT scans using the 18F-fluorothymidine tracer with routine staging 18F-FDG PET/CT scans found that 18F-FLT allowed for monitoring of changes in the cellular spread of nonsmall-cell lung cancer during chemo-radiotherapy. The findings show that the 18F-FLT tracer could be useful in improving NSCLC treatments based on patients' response.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ